Richard A. Heyman Sells 518 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 518 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total value of $14,265.72. Following the completion of the sale, the director now directly owns 128,585 shares of the company’s stock, valued at approximately $3,541,230.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enliven Therapeutics Trading Up 0.8 %

ELVN traded up $0.21 on Thursday, hitting $25.51. The company had a trading volume of 308,043 shares, compared to its average volume of 262,300. The company’s fifty day moving average price is $23.19 and its 200 day moving average price is $21.84. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67. The firm has a market cap of $1.20 billion, a P/E ratio of -12.82 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ELVN. Robert W. Baird assumed coverage on Enliven Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target on the stock. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently added to or reduced their stakes in ELVN. First Turn Management LLC purchased a new position in shares of Enliven Therapeutics in the 2nd quarter valued at about $9,657,000. Janus Henderson Group PLC lifted its stake in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares during the last quarter. Marshall Wace LLP acquired a new position in Enliven Therapeutics during the 2nd quarter worth approximately $4,489,000. Baker BROS. Advisors LP purchased a new stake in shares of Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Finally, Nicholas Investment Partners LP acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $1,310,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.